VF
NRIX icon

Virtu Financial’s Nurix Therapeutics NRIX Stock Holding History

Virtu Financial’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$205K Buy
+13,256
New +$220K 0.01% 1015
2021
Q3 		– Sell
-7,574
Closed -$201K – 1816
2021
Q2 		$201K Buy
+7,574
New +$222K 0.02% 993

Other funds holding NRIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return

Virtu Financial's NRIX Position: Q1 2026 in Review

Virtu Financial opened a new position in Nurix Therapeutics (NRIX) in Q1 2026: 13,256 shares worth $205K. The stake represents 0.01% of the portfolio and ranks #1015 among its holdings. This is a return to the name: Virtu Financial previously reported a position in NRIX as recently as Q2 2021.

Virtu Financial first reported a position in NRIX in Q2 2021 and has held it in 2 quarters since. 195 funds tracked by Wall St. Rank hold NRIX as of Q1 2026.

  • Virtu Financial held 13,256 shares of Nurix Therapeutics worth $205K as of Q1 2026.
  • Nurix Therapeutics was a new Virtu Financial position in Q1 2026.
  • Nurix Therapeutics made up 0.01% of Virtu Financial's portfolio in Q1 2026, its #1015 holding.
  • Virtu Financial first reported a position in Nurix Therapeutics in Q2 2021 and has held it in 2 quarters since.
  • 195 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q1 2026.

Based on Virtu Financial's 13F filing for Q1 2026, filed 14 May 2026.